Global Carcinoembryonic Antigen Market is expected to reach USD
2.56 Billion by 2022, according to a new study by Grand View Research, Inc.
Constant technological advancements pertaining to the development of novel
biomarkers which can be used in combination with other biomarkers is expected
to boost usage rates over the forecast period. Furthermore, the increasing
prevalence of cancer is expected to heighten the demand for effective
diagnostic tools. According to the WHO estimates in 2012, global cancer
incidences were nearly 14.1 million, which include 6.7 million female patients
and 7.4 million male patients. Increasing demand for minimally invasive
diagnostics procedures is also expected to play a vital role in determining
market growth. Key advantages associated with minimally invasive diagnostics
procedures include elevated patient satisfaction levels as they entail minor
incision wounds. In addition, these procedures involve relatively lesser
hospital stays and therefore, are economically viable and involve fewer post
procedure complications.
Browse full research report on Global
Carcinoembryonic Antigen (CEA) Market: http://www.grandviewresearch.com/industry-analysis/carcinoembryonic-antigen-cea-market
Further key findings from
the study suggest:
- Colorectal cancer was one of the largest revenue generating application segment of the carcinoembryonic antigen market and was estimated at USD 639.65 million in 2014. Increasing prevalence of colorectal cancer and usage of carcinoembryonic antigen tests at various stages is one of the critical factors accounting for its large share. For instance, in 2012, new cases of colorectal cancer were estimated to be over 93,000 and death due to colorectal cancer is expected to be over 49,700 in the U.S alone.
- Carcinoembryonic antigen based breast cancer diagnosis is identified as the most lucrative application segment of the market. The market is driven by factors such as growing number of female population above 50 years, growing demand for Hormone Replacement Therapy (HRT) and cosmetic surgeries. Moreover, growing patient awareness levels and the presence of favorable government initiatives are expected to improve treatment rates over the forecast period.
- North America was the largest regional market in 2014 owing to, the presence of high incidence rates, presence of favorable reimbursement framework, and high consumer awareness levels coupled with relatively higher healthcare expenditure levels.
- Asia Pacific is anticipated to witness the most lucrative growth over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and improving patient awareness levels are some factors accounting for this rapid growth.
- Key players operating in carcinoembryonic antigen market include Abbott Diagnostics, Quest Diagnostics, Roche Diagnostics, GenWay Biotech Inc. and Correlogic Systems, Inc.
Browse more reports of this category by Grand View http://www.grandviewresearch.com/industry/biotechnology
For the purpose of this study, Grand View Research has
segmented the carcinoembryonic antigen market on the basis of application, and
region:
Carcinoembryonic Antigen Application Outlook (Revenue,
USD Million, 2012 - 2022)
- Colorectal cancer
- Pancreatic cancer
- Ovarian cancer
- Breast cancer
- Thyroid cancer
- Others
Carcinoembryonic Antigen Regional Outlook (Revenue, USD
Million, 2012 - 2022)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Spain
- Asia Pacific
- China
- Japan
- India
- MEA
- South Africa
- Latin America
- Brazil
- Mexico
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment